Innovation + Divide...
Health Care: Drugs
OSI Pharmaceuticals Inc (OSIP: NASDAQ)
$57.49 -0.01 | -0.02%
06/08/10 - 04:00 PM ET
4.75M / 2.54M
Vol / Avg. Vol:57.49 / 57.50
Open / Prev. Close:57.48 - 57.51
Today's Range:33.51 - 60.42
52 Wk Range:85.09%
Performance YTD:TheStreet Rating:
Portfolios with OSIP
- Portfolio NameUser Type
- ContributorBarron's Activist Stocks 6-...
- UserASCO 2010
- ContributorBarron's Activist Stocks 4-...
- ContributorFast Money's Options Activi...
- ContributorFast Money's Top M&A St...
- UserJswaim
- ContributorBarron's Insider Purchases ...
- UserPART 4 JPMorgan 28th Annual...
- ContributorBarron's Summary 7-25-2009
- ContributorFast Money's Cancer Breakth...
Latest OSIP Headlines from TheStreet
- Allos: Folotyn Survival Trend in Lung Cancer 07.28.10 | 08:07 am
- Empire State Index: Monday's Headlines 05.17.10 | 09:05 am
- Astellas Agrees to Buy OSI Pharma for $4B 05.17.10 | 03:05 am
- 3 Stocks I Saw on TV
03.31.10 | 08:03 am - OSI Pharma, Biogen, Teva Rise to Highs 03.19.10 | 04:03 pm
- Stock Wrap: The Real Story, March 12 03.12.10 | 04:03 pm
- Bristol-Myers: Analysts' Upgrades, Downgrades 03.02.10 | 09:03 am
- OSI Shares Soar After Astellas Hostile Bid 03.02.10 | 12:03 am
- Astellas In Hostile Bid for OSI: BioBuzz 03.01.10 | 06:03 am
- Biotech Calendar: Key Dates for January 01.04.10 | 12:01 am
Press Releases for OSIP
- Astellas Completes Acquisition Of OSI Pharmaceuticals - PR Newswire 06.09.10 | 03:06 am
- Astellas Announces Successful Completion Of Tender Offer For Shares Of OSI - PR Newswire 06.08.10 | 03:06 am
- Astellas Announces Successful Completion Of Initial Tender Offer For Shares Of OSI And Announces Subsequent Offer Period - PR Newswire 06.03.10 | 03:06 am
- Expiration Date Of OSI Offer Extended To June 2, 2010 - PR Newswire 05.17.10 | 01:05 pm
- Astellas Pharma Inc. To Acquire OSI Pharmaceuticals, Inc. - PR Newswire 05.16.10 | 08:05 pm
- OSI Pharmaceuticals Announces That Tarceva® Received Approval In The European Union For Maintenance Use In Advanced Non-Small Cell Lung Cancer - Business Wire 04.29.10 | 01:04 am
- OSI Pharmaceuticals Announces That “RADIANT”, An International Phase III Tarceva Adjuvant Trial In Non-Small Cell Lung Cancer, Completes Enrollment - Business Wire 04.26.10 | 08:04 am
- Expiration Date Of OSI Offer Extended To May 17, 2010 - PR Newswire 04.23.10 | 04:04 am
- FDA Approves Tarceva As A Maintenance Therapy For Advanced Non-Small Cell Lung Cancer - Business Wire 04.16.10 | 08:04 pm
- OSI Pharmaceuticals Announces Conversion Period For Convertible Notes - Business Wire 04.01.10 | 05:04 pm
Partner Headlines for OSIP
- Companies Give Back Q1 Gains - What Could Spark Q3? - Seeking Alpha 07.19.10 | 07:07 am
- Company News for July 14, 2010 - Corporate Summary - Zacks 07.14.10 | 10:07 am
- Merger Arbitrage Mondays: May 24, 2010 - Seeking Alpha 05.25.10 | 06:05 am
- Dan Loeb's Hedge Fund Third Point Starts Multiple New Positions, Exits Citigroup - Seeking Alpha 05.24.10 | 05:05 pm
- Big Pharma's Emerging Market Fever: Abbott Aims for the Top of India's Industry - Seeking Alpha 05.23.10 | 11:05 am
- Astellas Seals the Deal With OSI After Rocky Courtship - Seeking Alpha 05.23.10 | 07:05 am
- Astellas Buyout of OSI Pharmaceuticals Gets More Likely - Seeking Alpha 05.19.10 | 11:05 am
- Astellas Finally Joins Peers With Major Overseas Acquisition - Seeking Alpha 05.18.10 | 04:05 am
- Wall St suffers after weak industrial report - Financial Times 05.17.10 | 09:05 pm
- Astellas / OSI - Financial Times 05.17.10 | 07:05 pm
